AlveoGene

An excellent paper that highlights the potential use of AlveoGene's InGenuITy®️ unique inhaled gene therapy platform. It provides a very firm foundation for risk mitigation and successful clinical translation of our AVG-002, AVG-003, and AVG-001 assets indication in lethal neonatal surfactant protein deficiencies SP-B, ABCA3 and AATD lung disease respectively.

For those of you who missed it, here is a helpful re-run of my Inv€$tival London 2024 presentation showcasing AlveoGene and our world leading data supporting our use of our #InGenuITy®️ inhaled gene therapy platform to transform rare respiratory disease outcomes and provide therapeutic solutions where there are none. https://we.tl/t-gob1uC1eO8 Looking forward to 2025... The best is very much to come so watch this space. Oxford Science Enterprises https://lnkd.in/eNXCesHE https://lnkd.in/dKxScD7b University of Oxford Imperial College London The University of Edinburgh

More great news for AlveoGene today with our novel inhaled gene therapy AVG-002 receiving Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency! Following fast on the heels of our recent Paediatric Rare Diseases Designation and enabled by our InGenuITy®️ platform, AVG-002 represents a potential first therapeutic solution for this key unmet medical need.

AlveoGene in the news!

Excellent news for AlveoGene today with confirmation of our Rare Paediatric Disease Designation from the FDA for AVG-002 indicated in lethal neonatal surfactant deficiency SP-B. This sets us on the pathway to developing a first-and-best-in-class product for this unmet medical need and provide a lasting therapeutic solution enabled by our inhaled gene therapy platform, InGenuITy®. Once approved, we will also qualify for the award of a Priority Review Voucher, which recently have secured associated valuations in the $100-150m range. We are also making excellent progress with AVG-003 indicated in ABCA3 surfactant deficiency, and data in hand supports AVG-001 becoming the preferred future product for the treatment of AATD lung disease.

AlveoGene in the news!

Excellent news for AlveoGene and our efforts in rare respiratory disease supporting the development of our InGenuITy® enabled assets in neonatal surfactant protein deficiencies SP-B (AVG-002) and ABCA3 (AVG-003) at pace.

AlveoGene is in Barcelona at the World Orphan Drug Congress this week. I am looking forward to sharing our latest developments as we seek to transform rare respiratory disease outcomes using inhaled gene therapy using #InGenuITy® platform. Our datasets in SP-B, ABCA3 and AATD lung disease are market leading and set a firm foundation for onward clinical development at pace. David Hipkiss is presenting at 16.10 hrs CET on Wed 23rd October and looks forward to welcoming you there. #WODC #OrphanDrug #RareDisease

I am delighted to be working with the Oxford-Harrington Rare Disease Centre this week at the 2024 Oxford Harrington Rare Disease Symposium which is taking place at Trinity College Oxford from 24th-26th September. I will be presenting AlveoGene's outstanding year of progress as we continue on our mission to transform rare respiratory disease outcomes using inhaled gene therapy. Our InGenuiTy® platform uniquely combines efficacy, durability and convenience with the potential for lifelong protection from a single dose. I will provide updates on our pipeline progress and latest developments in neonatal surfactant protein deficiencies (Lethal SP-B and ABCA3), Alpha-1 anti-trypsin deficency (AATD), and IPF. Please join me at 15-05 hrs on Wednesday 25th September in the Levine Building at Trinity College, Oxford. And to learn more, visit www.alveogene.com

A great piece of BiotechTV from AlveoGene Investor Director and Oxford Science Enterprises Partner Claire Brown showcasing OSE Investment philosophy and modus operandi. https://lnkd.in/gbRJM6rs To learn more about how AlveoGene are using inhaled gene therapy and our #InGenuiTy platform to transform rare respiratory disease outcomes visit us at www.alveogene.com.